Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham; GRADE not reported.
1 finding from 1 review
Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
QoL · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low
Chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin… compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Intervention not reported
PEG 400 vs. HP‐guar · people with dry eye
1 finding from 1 review
Intervention not reported
Trehalose + hyaluronic acid vs. PEG + PG + HP‐guar · people with dry eye
1 finding from 1 review
Intervention not reported
PEG 400 + PG + HP‐guar vs. CMC · people with dry eye
1 finding from 1 review
Intervention not reported
PEG 400 + PG or sodium hyaluronate vs. HPMC or CMC · people with dry eye
1 finding from 1 review
Intervention not reported
0.4% PEG 400 + PG vs. 0.25% PEG 400 · people with dry eye
1 finding from 1 review
Intervention not reported
0.25% PEG 400 vs.1% CMC · people with dry eye
1 finding from 1 review
Intervention not reported
0.25% PEG 400 vs. 0.3% HPMC · people with dry eye
1 finding from 1 review
Intervention not reported
Change in 9‐hole peg test (HPT) at 12 months (seconds) · adults with CMT1A
1 finding from 1 review
Change in 9‐hole peg test (HPT) at 12 months (seconds) · people with fatigue in peripheral neuropathy
1 finding from 1 review
Intervention not reported
Peg interferon vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes peg interferon vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Peg interferon plus ribavirin vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes peg interferon plus ribavirin vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Ribavirin plus peg interferon vs.peg interferon · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes ribavirin plus peg interferon vs.peg interferon (very low certainty).
1 finding from 1 review
Overall survival · children and adolescents (< 18 years of age) with first‐line ALL
1 finding from 1 review